Bavarian Nordic A/S - Report on the Results of the Extraordinary General Meeting, held 15 May 2007

In accordance with the agenda an Extraordinary General Meeting of Bavarian      
Nordic A/S was held today 15 May 2007.                                          

The General Assembly adopted the Board of Directors' proposal to amend:         

§ 4 of the Articles of Association (stock split);                               
§ 5a of the Articles of Association (Authorisation for Increase of the Company's
Share Capital);                                                                 
§ 5b of the Articles of Association (Authorization for issuing Warrants for     
Employees);                                                                     
§ 8 of the Articles of Association (Keeper of Stock Register);                  
§ 10, sub-section 6 of the Articles of Association (Distribution of printed     
information).                                                                   



Kvistgård, 15 May 2007                                                          



Asger Aamund                                                                    
Chairman                                                                        

Contacts:	
Peter Wulff, President & CEO                                          
Telephone: +45 33 26 83 83                                                     

About Bavarian Nordic A/S:                                                      
Bavarian Nordic (CSE: BAVA) is a leading international biopharmaceutical company
developing and producing inno­vative vaccines to prevent and treat infectious   
diseases and cancer. With operations in Denmark, Germany, the USA, and          
Singapore, Bavarian Nordic employs over 200 people. Bavarian Nordic's patented  
technology, MVA-BN®, is as been demonstrated in clinicial studies, one of the   
world's safest, multivalent vac­cine vectors for the development of vaccines    
against various infectious diseases such as smallpox, HIV/AIDS, as well as      
against breast and prostate cancer. Several MVA-BN®-based HIV and smallpox      
vaccines are in clinical Phase I and Phase II trials. Bavarian Nordic has       
ongoing development contracts with the US government to develop IMVAMUNE® as a  
safe third-generation smallpox vaccine. Bavarian Nordic has supplied several    
other governments with smallpox vaccines.                                       
For more information please visit www.bavarian-nordic.com                       

“Safe Harbour" Statement Under the Private Securities Litigation Reform Act of  
1995:                                                                           
Except for the historical information contained herein, this release contains   
"forward-looking state­ments" within the meaning of the Private Securities      
Reform Act of 1995. No "forward-looking state­ment" can be guaranteed, and      
actual results may differ materially from those projected. Bavarian Nor­­dic    
undertakes no obligation to publicly update any "forward-looking statement",    
whether as a re­sult of new information, future events, or otherwise. Additional
information regarding risks and unce­rtainties is set forth in the current      
Annual Report, which we incorporate by reference.